DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer
Large Cell Neuroendocrine Lung Carcinoma
Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology

Interventions

DRUG: Obrixtamig
DRUG: ZL-1310
DRUG: Atezolizumab

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]